Therapeutic Antibodies

#Allogene Therapeutics #allogeneic cell therapies #Biologics #Biotech #Cancer Research Horizons #Cancer vaccine #CAR-T #Cell therapy #Clinical trials #Drug discovery #Financing #Funding #LifeArc #Oncology #Rare disease #Research and development #Seed funding #Start-ups #University of Dundee #University of Oxford

This week in drug discovery (29 April – 3 May) 

News round-up for 29 April – 3 May by DDW Multimedia Editor Megan Thomas. The ongoing innovation and development in the drug discovery sector relies on a number of moving parts, one of which is financial support and backing. Whether it is successful seed funding or dedicated investment,… Read More

#News

Child receiving treatment for malaria
#Africa #Clinical trial #Malaria #Monoclonal antibodies #Therapeutic Antibodies

Experimental malaria monoclonal antibody prevents infection

A single injection of an experimental monoclonal antibody called L9LS was 77% effective at preventing malaria infection in children in Mali, according to the results of a mid-stage clinical trial. L9LS binds to and neutralises ‘sporozoites’, the form of the malaria parasite transmitted by mosquitoes that… Read More

#News #Trending News

#Antibodies #Artificial intelligence (AI) #Monoclonal antibodies #Therapeutic Antibodies

Therapeutic antibody potential in 2024

DDW’s Megan Thomas speaks to industry experts and thought leaders about the potential for therapeutic antibodies in 2024. Many of the best-selling drugs in 2023 were monoclonal antibody (mAB) therapies, including Keytruda (pembrolizumab), Humira (adalimumab), and Dupixent (dupilumab)1. This won't come as a surprise when you look at industry milestones… Read More

#Exclusive Content

Seed fund
#Biologics #Seed funding #Start-ups #University of Dundee

Dundee spin-out raises £4m to advance VLPs

Glen Clova Scientific has closed a £4 million (approximately $5 million) seed financing round, led by Norcliffe Capital together with investment from DSW Ventures, TRICAPITAL Angels and Scottish Enterprise. Glen Clova Scientific was founded in 2022 as a spin out from the University of Dundee to… Read More

#News #Start-up Zone

Monoclonal antibody
#Antibodies #Drug discovery #eBook #Monoclonal antibodies #Therapeutic Antibodies

eBook: Drug discovery and the impact of mAbs

The low toxicity and high specificity of monoclonal antibodies (mAbs) continue to make them an appealing target for clinical research and investment. During 2023, 16 antibody therapeutics were granted approvals in the US or EU, either for the first time or for a new indication, covering uses as… Read More

#News

Human antibodies
#Antibodies #Antibody discovery workflow #Antibody-based therapeutics #Monoclonal antibodies #Therapeutic Antibodies

Opportunity in the antibody market: Hear from the experts

Join DDW for this free event ‘Where is the opportunity in the therapeutic antibody market?’, which is co-sponsored by Bio-Rad and Benchling. The event will take place on 30 April at 3PM BST / 4pm CEST / 10am EDT / 7am PDT. Read More

Webinar date:
Co-sponsored by Benching and Bio-Rad
#News

#Drug discovery #Therapeutic Antibodies

ebook: Drug discovery and the impact of mAbs

This eBook sponsored by Thermo Fisher Scientific explores the impact of monoclonal antibodies (mAbs) on the treatment of cancer, autoimmune and infectious diseases, and inflammatory conditions, as well as the latest clinical research and where the innovation in mAb development might be in the future. Download this exclusive eBook… Read More

#DDW eBooks

#Antibodies #Artificial intelligence (AI) #Biologics #Investment #Seed funding #Start-ups

AI drug discovery company Xaira launches with $1b investment

Xaira Therapeutics, a joint incubation by ARCH Venture Partners and Foresite Labs, has launched with more than $1 billion of committed capital from lead investors. Xaira is building a platform for drug discovery and development that it hopes will advance multiple drug programmes and unlock biological… Read More

#News #Start-up Zone #Trending News

Laboratory research
#Antibody binding #Bioanalytics #Biologics #Biotherapeutics #Characterisation #High Throughput #QA/QC #Webinar

Next week: Accelerate development of advanced biotherapeutics

Join DDW for this free event, ‘Higher throughput bioanalytical methods accelerate the development and evaluation of advanced biotherapeutics’, which is supported by Revvity. It will take place on 2 May at 3pm BST, 10am EDT, 4pm CEST and will be presented by Ron… Read More

Webinar date:
Brought to you by Revvity
#News

#Antibodies #Antiverse #Artificial intelligence (AI) #Generative AI #Oncology

Advancing antibody cancer therapeutics with AI

Antiverse is an artificial intelligence (AI)-driven company that specialises in antibody design against difficult-to-drug targets, including G-protein coupled receptors (GPCRs) and ion channels. Murat Tunaboylu, Co-founder and CEO of Antiverse, speaks with Megan Thomas about how AI can advance therapeutic antibody design. Megan T: How is Antiverse using AI in… Read More

#Cancer Research #Exclusive Content

Monoclonal antibodies
#Antibodies #Antibody discovery workflow #Antibody-based therapeutics #Monoclonal antibodies #Therapeutic Antibodies

Webinar: How can we develop better therapeutic antibodies?

Join DDW for this free event ‘Where is the opportunity in the therapeutic antibody market?’, which is co-sponsored by Bio-Rad and Benchling. The event will take place on 30 April at 3PM BST / 4pm CEST / 10am EDT / 7am PDT. Read More

Webinar date:
Co-sponsored by Benching and Bio-Rad
#News

Two scientists working in a research laboratory
#Antibody binding #Bioanalytics #Biologics #Biotherapeutics #Characterisation #High Throughput #QA/QC #Webinar

Accelerate the development of advanced biotherapeutics

Join DDW for this free event, ‘Higher throughput bioanalytical methods accelerate the development and evaluation of advanced biotherapeutics’, which is supported by Revvity. It will take place on 2 May at 3pm BST, 10am EDT, 4pm CEST and will be presented by Ron… Read More

Webinar date:
Brought to you by Revvity
#News

#Antibodies #Cancer research #Oncology #Phase III trial #Therapeutic Antibodies

Improving the standard of care: Inside the DUO-E trial

Professor Shannon Westin is principal investigator of the DUO-E trial, here she speaks to DDW’s Megan Thomas about why the standard of care needs improving and the impact of therapeutic antibodies such as durvalumab. The DUO-E trial is a three-arm, randomised, double-blind, placebo-controlled, multicentre Phase III trial assessing the combination… Read More

#Cancer Research #Exclusive Content

Antibodies
#Antibodies #Antibody discovery workflow #Antibody-based therapeutics #Monoclonal antibodies #Therapeutic Antibodies

Webinar: Innovations and opportunities in the therapeutic antibody market

Join DDW for this free event ‘Where is the opportunity in the therapeutic antibody market?’, which is co-sponsored by Bio-Rad and Benchling. The event will take place on 30 April at 3PM BST / 4pm CEST / 10am EDT / 7am PDT. Read More

Webinar date:
Co-sponsored by Benching and Bio-Rad
#News

#Absci #Antibodies #Artificial intelligence (AI) #Biologics #Generative AI #Interview

The next generation of AI

Reece Armstrong speaks to Sean McClain, Founder & CEO of Absci, about the rise of generative AI in life sciences. The company has a biologics pipeline with a focus on differentiated antibodies targeting a range of indications.  Last year, a lot of focus was placed on artificial intelligence (AI) both… Read More

#Exclusive Content

Medical researchers
#Antibody binding #Bioanalytics #Biologics #Biotherapeutics #Characterisation #High Throughput #QA/QC #Webinar

How to accelerate the development of advanced biotherapeutics

Join DDW for this free event, ‘Higher throughput bioanalytical methods accelerate the development and evaluation of advanced biotherapeutics’, which is supported by Revvity. It will take place on 2 May at 3pm BST, 10am EDT, 4pm CEST and will be presented by Ron… Read More

Webinar date:
Brought to you by Revvity
#News